Harbin Gloria Pharmaceuticals (002437) - Net Assets
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has net assets worth CN¥2.18 Billion CNY (≈ $318.68 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.03 Billion ≈ $443.38 Million USD) and total liabilities (CN¥852.18 Million ≈ $124.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Harbin Gloria Pharmaceuticals liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.18 Billion |
| % of Total Assets | 71.87% |
| Annual Growth Rate | 16.92% |
| 5-Year Change | 2.07% |
| 10-Year Change | -43.19% |
| Growth Volatility | 149.92 |
Harbin Gloria Pharmaceuticals - Net Assets Trend (2007–2024)
This chart illustrates how Harbin Gloria Pharmaceuticals's net assets have evolved over time, based on quarterly financial data. Also explore 002437 total assets for the complete picture of this company's asset base.
Annual Net Assets for Harbin Gloria Pharmaceuticals (2007–2024)
The table below shows the annual net assets of Harbin Gloria Pharmaceuticals from 2007 to 2024. For live valuation and market cap data, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.97 Billion ≈ $288.69 Million |
+15.36% |
| 2023-12-31 | CN¥1.71 Billion ≈ $250.26 Million |
+0.39% |
| 2022-12-31 | CN¥1.70 Billion ≈ $249.28 Million |
-13.92% |
| 2021-12-31 | CN¥1.98 Billion ≈ $289.58 Million |
+2.38% |
| 2020-12-31 | CN¥1.93 Billion ≈ $282.85 Million |
+21.68% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.45 Million |
-63.85% |
| 2018-12-31 | CN¥4.39 Billion ≈ $642.95 Million |
+3.32% |
| 2017-12-31 | CN¥4.25 Billion ≈ $622.28 Million |
+5.09% |
| 2016-12-31 | CN¥4.05 Billion ≈ $592.15 Million |
+16.52% |
| 2015-12-31 | CN¥3.47 Billion ≈ $508.18 Million |
+11.95% |
| 2014-12-31 | CN¥3.10 Billion ≈ $453.95 Million |
+25.17% |
| 2013-12-31 | CN¥2.48 Billion ≈ $362.66 Million |
+4.98% |
| 2012-12-31 | CN¥2.36 Billion ≈ $345.46 Million |
+7.44% |
| 2011-12-31 | CN¥2.20 Billion ≈ $321.54 Million |
+3.61% |
| 2010-12-31 | CN¥2.12 Billion ≈ $310.33 Million |
+637.57% |
| 2009-12-31 | CN¥287.53 Million ≈ $42.07 Million |
+48.18% |
| 2008-12-31 | CN¥194.04 Million ≈ $28.39 Million |
+40.24% |
| 2007-12-31 | CN¥138.36 Million ≈ $20.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Harbin Gloria Pharmaceuticals's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 847.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥2.28 Billion | 116.87% |
| Other Comprehensive Income | CN¥-3.09 Million | -0.16% |
| Other Components | CN¥354.78 Million | 18.19% |
| Total Equity | CN¥1.95 Billion | 100.00% |
Harbin Gloria Pharmaceuticals Competitors by Market Cap
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Veken Elite
SHG:600152
|
$1.15 Billion |
|
Zhejiang JW Precision Machinery Co.Ltd
SHE:300984
|
$1.15 Billion |
|
TTW Public Company Limited
BK:TTW
|
$1.15 Billion |
|
TTW Public Company Limited
BK:TTW-R
|
$1.15 Billion |
|
Jiangsu Libert Inc
SHG:605167
|
$1.15 Billion |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
$1.15 Billion |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
$1.15 Billion |
|
ABOUT YOU Holding AG
F:YOU
|
$1.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harbin Gloria Pharmaceuticals's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,661,773,347 to 1,950,697,287, a change of 288,923,940 (17.4%).
- Net income of 232,759,457 contributed positively to equity growth.
- Dividend payments of 9,358,200 reduced retained earnings.
- Share repurchases of 1,190,118 reduced equity.
- Other comprehensive income decreased equity by 1,724,172.
- Other factors increased equity by 68,436,973.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥232.76 Million | +11.93% |
| Dividends Paid | CN¥9.36 Million | -0.48% |
| Share Repurchases | CN¥1.19 Million | -0.06% |
| Other Comprehensive Income | CN¥-1.72 Million | -0.09% |
| Other Changes | CN¥68.44 Million | +3.51% |
| Total Change | CN¥- | 17.39% |
Book Value vs Market Value Analysis
This analysis compares Harbin Gloria Pharmaceuticals's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 40.05x to 4.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.09 | CN¥3.52 | x |
| 2008-12-31 | CN¥0.12 | CN¥3.52 | x |
| 2009-12-31 | CN¥0.18 | CN¥3.52 | x |
| 2010-12-31 | CN¥1.15 | CN¥3.52 | x |
| 2011-12-31 | CN¥1.04 | CN¥3.52 | x |
| 2012-12-31 | CN¥1.11 | CN¥3.52 | x |
| 2013-12-31 | CN¥1.12 | CN¥3.52 | x |
| 2014-12-31 | CN¥1.43 | CN¥3.52 | x |
| 2015-12-31 | CN¥1.55 | CN¥3.52 | x |
| 2016-12-31 | CN¥1.80 | CN¥3.52 | x |
| 2017-12-31 | CN¥1.90 | CN¥3.52 | x |
| 2018-12-31 | CN¥1.97 | CN¥3.52 | x |
| 2019-12-31 | CN¥0.69 | CN¥3.52 | x |
| 2020-12-31 | CN¥0.84 | CN¥3.52 | x |
| 2021-12-31 | CN¥0.86 | CN¥3.52 | x |
| 2022-12-31 | CN¥0.74 | CN¥3.52 | x |
| 2023-12-31 | CN¥0.76 | CN¥3.52 | x |
| 2024-12-31 | CN¥0.86 | CN¥3.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harbin Gloria Pharmaceuticals utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.93%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.54%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.45x
- Recent ROE (11.93%) is above the historical average (5.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 54.05% | 45.55% | 0.76x | 1.56x | CN¥60.93 Million |
| 2008 | 54.60% | 38.44% | 0.99x | 1.44x | CN¥86.55 Million |
| 2009 | 45.29% | 30.29% | 0.97x | 1.54x | CN¥101.48 Million |
| 2010 | 7.30% | 26.89% | 0.26x | 1.03x | CN¥-57.36 Million |
| 2011 | 5.39% | 21.39% | 0.24x | 1.07x | CN¥-99.96 Million |
| 2012 | 7.06% | 23.17% | 0.28x | 1.10x | CN¥-68.52 Million |
| 2013 | 9.48% | 17.34% | 0.44x | 1.23x | CN¥-12.37 Million |
| 2014 | 14.69% | 23.28% | 0.39x | 1.63x | CN¥141.65 Million |
| 2015 | 19.54% | 24.79% | 0.32x | 2.44x | CN¥324.50 Million |
| 2016 | 18.08% | 24.02% | 0.34x | 2.19x | CN¥320.34 Million |
| 2017 | 7.42% | 10.18% | 0.34x | 2.17x | CN¥-107.72 Million |
| 2018 | 2.91% | 2.30% | 0.58x | 2.19x | CN¥-306.51 Million |
| 2019 | -174.51% | -52.53% | 0.79x | 4.21x | CN¥-2.81 Billion |
| 2020 | 21.67% | 13.10% | 0.68x | 2.45x | CN¥215.43 Million |
| 2021 | 2.38% | 1.43% | 0.67x | 2.48x | CN¥-144.38 Million |
| 2022 | -17.75% | -9.32% | 0.76x | 2.50x | CN¥-452.64 Million |
| 2023 | 7.24% | 4.58% | 0.83x | 1.90x | CN¥-45.84 Million |
| 2024 | 11.93% | 9.54% | 0.86x | 1.45x | CN¥37.69 Million |
Industry Comparison
This section compares Harbin Gloria Pharmaceuticals's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harbin Gloria Pharmaceuticals (002437) | CN¥2.18 Billion | 54.05% | 0.39x | $1.15 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more